We Have Effective Treatment for Hepatitis C. So Why Don’t States Give It to 100,000 Inmates?

Seventeen percent of prisoners in America are infected.

jarun011/iStock

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.


Less than 1 percent of inmates with hepatitis C are receiving treatment in state prisons, according to a new study by prison officials, doctors, and researchers. It’s largely because prisons can’t afford the drugs they need to fight the dangerous liver disease that spreads through blood and bodily fluids.

Hepatitis C kills more Americans than any other infectious disease, including HIV and tuberculosis; about 17 percent of the prison population in America is suffering from it, compared with 1 percent of the general population. New treatments have been developed but are extremely expensive, so over the last two years, inmates in Tennessee, Massachusetts, Minnesota, and Pennsylvania have sued for access to the drugs.

The study, published in Health Affairs, comes on the heels of those lawsuits. It was conducted by researchers at Yale University in collaboration with the Association of State Correctional Administrators, which includes the heads of corrections agencies in every state as well as the Federal Bureau of Prisons. Researchers collected data from 41 states about hepatitis C infections and treatment in prisons. They found that more than 106,000 inmates in state prisons had the disease as of January 2015, and of those, only about 950, or less than 0.9 percent were being treated.

“What we desperately need are less costly drugs and more funding.” 

Prison officials who helped conduct the study have blamed the high cost of treatment. In 2013, new drugs were released that have proved very effective, curing the infection in 90 percent of cases in a few months. (Previous treatment options cured roughly half of cases, took much longer, and resulted in debilitating side effects.) But the cost of the new drugs can be prohibitive: A 12-week course of medication can range from $54,600 to $94,500, depending on the particular drug.

Some government agencies can get discounts. The federal prison system receives 24 percent off, while the Department of Veterans Affairs may have a discount of 50 percent, the researchers found. But state prisons aren’t so lucky. Many of them get a discount of less than 10 percent, and one state gets no discount at all. As a result, state prison officials say they must make tough choices about whom to treat.

Treating hepatitis C patients “requires resources and discounts we don’t have,” A.T. Wall, director of the Rhode Island Department of Corrections and a co-author of the study, said in a statement. “What we desperately need are less costly drugs and more funding.”

Corrections departments in 16 states reported spending at least 10 percent of their total budget for drugs on hepatitis C medication. But states could actually save money in the long run if they invest in treatment right away, the researchers noted. When left untreated, patients with hepatitis C may need a liver transplant, which can cost hundreds of thousands of dollars, and they can spread the infection to others. To get the drugs for less money, the researchers encouraged state prisons to partner with qualified health centers that can receive discounts through a federal program.

Thomas Castelli, an attorney for the American Civil Liberties Union who is representing inmates in Tennessee, said in a statement, “Incarcerating people under conditions that erode their health, safety and human dignity amounts to cruel and unusual punishment, which not only has devastating long-term effects for those individuals, but which undermines the purported purpose of a rehabilitative criminal justice system.”

Health Affairs

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. It's our first time asking for an outpouring of support since screams of FAKE NEWS and so much of what Trump stood for made everything we do so visceral. Like most newsrooms, we face incredibly hard budget realities, and it's unnerving needing to raise big money when traffic is down.

So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

IT'S NOT THAT WE'RE SCREWED WITHOUT TRUMP:

"It's that we're screwed with or without him if we can't show the public that what we do matters for the long term," writes Mother Jones CEO Monika Bauerlein as she kicks off our drive to raise $350,000 in donations from readers by July 17.

This is a big one for us. So, as we ask you to consider supporting our team's journalism, we thought we'd slow down and check in about where Mother Jones is and where we're going after the chaotic last several years. This comparatively slow moment is also an urgent one for Mother Jones: You can read more in "Slow News Is Good News," and if you're able to, please support our team's hard-hitting journalism and help us reach our big $350,000 goal with a donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate